Activating Compound | Comment | Organism | Structure |
---|---|---|---|
dGTP | dGTP causes ISF1 to tetramerize, activating its catalytic activity. Isoform ISF2 has dGTP-independent catalytic activity | Mus musculus |
Cloned (Comment) | Organism |
---|---|
expression in 293T cell | Mus musculus |
Protein Variants | Comment | Organism |
---|---|---|
P635A | mutation retains antiviral activity of ISF1, and increased its catalytic activity to that of ISF2 | Mus musculus |
T634A | mutation retains antiviral activity of ISF1 | Mus musculus |
T634E | mutation in ISF1, mimics phosphorylated SAMHD1. Mutant is inactive | Mus musculus |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Mus musculus | Q60710 | isoform 1 | - |
Posttranslational Modification | Comment | Organism |
---|---|---|
phosphoprotein | isoform ISF1 is phosphorylated at amino acids Ser49, Thr52, Ser55, Thr56, Thr310, and Thr634 with frequencies ranging from 21% to 56% | Mus musculus |
Source Tissue | Comment | Organism | Textmining |
---|
General Information | Comment | Organism |
---|---|---|
physiological function | in the mouse, SAMHD1 is expressed as isoforms ISF1 and ISF2 that differ at the carboxyl terminus due to alternative splicing of the last coding exon. Both isoforms are antiviral in nondividing cells. Phosphomimetic mutation at Thr-634 of ISF1 ablates its antiviral activity but has little effect on phosphohydrolase activity in vitro. dGTP causes ISF1 to tetramerize, activating its catalytic activity. Isoform ISF2 lacks the phosphorylation site, is significantly more active, tetramerizes, and is active without added dGTP. Mouse SAMHD1 does not degrade HIV-1 genomic viral RNA | Mus musculus |